Home / Health / Johnson & Johnson, AstraZeneca to resume trial for Covid-19 vaccine

Johnson & Johnson, AstraZeneca to resume trial for Covid-19 vaccine

Earlier, AstraZeneca said it had been cleared by the FDA to restart a trial that had been halted in the U.S. after a volunteer participating in a U.K. trial of the shot had fallen ill

Premium

Allowing the studies to go forward removes a shadow that had been hanging over the effort to find a vaccine in recent weeks. Photo: Bloomberg

Riley Griffin, Robert Langreth and Suzi Ring | Bloomberg

4 min read Last Updated : Oct 25 2020 | 6:32 AM IST

AstraZeneca Plc and Johnson & Johnson plan to resume Covid-19 vaccine clinical trials that had been halted by U.S. regulators, putting research into two of the leading candidates for a coronavirus inoculation back on track.

Johnson & Johnson said in a statement Friday it is preparing to resume recruitment in a late-stage trial of its vaccine after consultation with the U.S. Food and Drug Administration. An independent data safety monitoring board recommended the trial continue. The study was paused earlier this month after a patient became sick, but the company said no clear cause of the illness had been identified.

Topics : Coronavirus Coronavirus Vaccine AstraZeneca Johnson and Johnson

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in